Fulcrum Therapeutics Inc
NASDAQ:FULC
Relative Value
The Relative Value of one FULC stock under the Base Case scenario is 2.93 USD. Compared to the current market price of 7.33 USD, Fulcrum Therapeutics Inc is Overvalued by 60%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
FULC Competitors Multiples
Fulcrum Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Fulcrum Therapeutics Inc
NASDAQ:FULC
|
453.8m USD | 161.8 | -4.7 | -2 | -2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
736B USD | 21.6 | 140.7 | 63.4 | 72.8 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17.1 | 47.6 | 34.8 | 37.9 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
363B USD | 4.4 | 9 | 11.9 | 15.8 | ||
US |
Merck & Co Inc
NYSE:MRK
|
326.6B USD | 5.4 | 894.7 | 44.5 | 86.9 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
188.7B GBP | 5.1 | 39.6 | 140.8 | 225.8 | ||
CH |
Novartis AG
SIX:NOVN
|
182B CHF | 4.3 | 13.4 | 9.8 | 16.2 | ||
CH |
Roche Holding AG
SIX:ROG
|
175.9B CHF | 3 | 15.3 | 8.7 | 10.3 |